Searched for: subject%3A%22alteplase%22
(1 - 9 of 9)
document
Rijken, D.C. (author), Barrett-Bergshoeff, M.M. (author), Jie, A.F.H. (author), Criscuoli, M. (author), Sakharov, D.V. (author), Gaubius Instituut TNO (author)
Amediplase (K2tu-PA) is a hybrid plasminogen activator, consisting of the kringle 2 domain of alteplase and the protease domain of urokinase. The objective of this study was to determine the in vitro clot penetration of amediplase in relation to its fibrin binding and to compare the properties with those of alteplase. The clot lysis activity of...
article 2004
document
Rosén, S. (author), Wejkum, L. (author), Billing-Claeson, S. (author), Ghosh, R. (author), Grdic, K. (author), Chmielewska, J. (author), Meijer, P. (author), Kluft, C. (author), Tengborn, L. (author), Conkie, J. (author), Walker, I. (author), Gaubius Instituut TNO (author)
A chromogenic bioimmunoassay method for determination of t-PA activities has been evaluated on plasmas from healthy individuals and from thromboembolic patients. The assay consists of an initial binding and washing step, whereby plasma t-PA is bound to a specific monoclonal t-PA antibody, which is coated on to microplate wells, followed by a...
article 1998
document
Rijken, D.C. (author), Jie, A.F.H. (author), Gaubius Laboratory TNO Preventie en Gezondheid (author)
Reteplase is a protein consisting of the kringle-2 and protease domains of tissue-type plasminogen activator (t-PA). Because intravenous heparin will be used as an adjunct to thrombolytic therapy with reteplase, we investigated the interactions in vitro between heparin and reteplase as well as between heparin and recombinant t-PA (alteplase) as...
article 1996
document
Wijnberg, M.J. (author), Nieuwenbroek, N.M.E. (author), Slomp, J. (author), Quax, P.H.A. (author), Verheijen, J.H. (author), Gaubius Laboratory TNO Preventie en Gezondheid (author)
The objective of this study was to investigate the role of the plasminogen activation system in the migration of human vascular smooth muscle cells in vitro. After wounding of confluent human smooth muscle cell cultures by stripping cells from their extracellular matrix, cells start to migrate from the wounded edge into the denuded area....
article 1996
document
Huisman, L.G.M. (author), van Griensven, J.M.T. (author), Kluft, C. (author), TNO Preventie en Gezondheid (author)
Standardisation of t-PA antigen and activity assays requires a t-PA standard which ideally is a single preparation suitable for all assays. Most t-PA preparations, however, are not homogeneous; they can contain several forms of t-PA: single-chain and two-chain t-PA, and two glycoforms (I and II). In this study, the behaviour of Actilyse...
article 1996
document
Haider, A.W. (author), Andreotti, F. (author), Hackett, D.R. (author), Tousoulis, D. (author), Kluft, C. (author), Maseri, A. (author), Davies, G.J. (author), Gaubius Instituut TNO (author)
Objectives. This study investigated the influence of early spontaneous intermittent reperfusion on the extent of myocardial damage and its relation to endogenous hemostatic activity, Background. In the early phase of acute myocardial infarction coronary occlusion is often intermittent, even before thrombolytic therapy is administered. The...
article 1995
document
Rijken, D.C. (author), Groeneveld, E. (author), Barrett-Bergshoeff, M.M. (author), Gaubius Laboratory TNO Preventie en Gezondheid (author)
BM 06.022 is a non-glycosylated mutant of human tissue-type plasminogen activator (t-PA) comprising only the kringle-2 and proteinase domains. The in vivo half-life of BM 06.022 antigen is 4- to 5-fold longer than that of t-PA antigen. The in vitro half-life of the activity of BM 06.022 at therapeutic concentrations in plasma is shorter than...
article 1994
document
Brommer, E.J.P. (author), van Bockel, J.H. (author), Gaubius Laboratorium Instituut voor verouderings- en vaatziekten onderzoek TNO (author)
Each of three distinct, concentric layers of human arterial thrombi, was analysed immunochemically for the plasminogen and fibrin content, and for the ex vivo susceptibility to thrombolysis by various thrombolytic agents in a saline or plasma milieu. The age of the thrombus layer determined: (a) the plasminogen content; (b) the fibrin content,...
article 1992
document
Emeis, J.J. (author), Verheijen, J.H. (author), Instituut voor Verouderings- en Vaatziekten Onderzoek TNO (author)
Chemicals/CAS: Recombinant Proteins; Tissue Plasminogen Activator, EC 3.4.21.68
article 1992
Searched for: subject%3A%22alteplase%22
(1 - 9 of 9)